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ABSTRACT
Fructose-2,6-bisphosphate (F2,6BP) is a shunt product of glycolysis that 
allosterically activates 6-phosphofructo-1-kinase (PFK-1) resulting in increased 
glucose uptake and glycolytic flux to lactate. The F2,6BP concentration is dictated by 
four bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4) 
with distinct kinase:phosphatase activities. PFKFB4 is over-expressed in human 
cancers, induced by hypoxia and required for survival and growth of several cancer 
cell lines. Although PFKFB4 appears to be a rational target for anti-neoplastic drug 
development, it is not clear whether its kinase or phosphatase activity is required for 
cancer cell survival. In this study, we demonstrate that recombinant human PFKFB4 
kinase activity is 4.3-fold greater than its phosphatase activity, siRNA and genomic 
deletion of PFKFB4 decrease F2,6BP, PFKFB4 over-expression increases F2,6BP and 
selective PFKFB4 inhibition in vivo markedly reduces F2,6BP, glucose uptake and ATP. 
Last, we find that PFKFB4 is required for cancer cell survival during the metabolic 
response to hypoxia, presumably to enable glycolytic production of ATP when the 
electron transport chain is not fully operational. Taken together, our data indicate 
that the PFKFB4 expressed in multiple transformed cells and tumors functions to 
synthesize F2,6BP. We predict that pharmacological disruption of the PFKFB4 kinase 
domain may have clinical utility for the treatment of human cancers. 
INTRODUCTION
Glucose metabolism is regulated by a family of 
four bifunctional 6-phosphofructo-2-kinase/ fructose-
2,6-bisphosphatases (PFKFB1-4) that determine the 
concentration of fructose 2,6-bisphosphate (F2,6BP), 
which is a potent allosteric activator of the glycolytic 
enzyme 6-phosphofructo-1-kinase (PFK-1) [1]. Whereas 
F2,6BP activates PFK-1, several metabolic products 
including ATP, H+ ions and citrate, allosterically inhibit 
PFK-1, indicating that PFK-1 is an essential metabolic 
sensor in the glycolytic pathway [2]. Given the central 
role that the PFKFB family members play in regulating 
glucose metabolism via PFK-1, understanding their 
specific functions within cells and tissues is of paramount 
importance to the study of a multitude of disease states 
caused by inflammation, ischemia and neoplastic 
transformation.
Within five years of the initial discovery of F2,6BP 
in 1980 [3, 4], multiple PFKFB enzyme activities were 
detected in several organs that were distinguished by 
having markedly reduced but still detectable fructose-
2,6-bisphosphatase activities relative to the liver PFKFB1 
family member which has a near 1:1 kinase:bisphosphatase 
ratio (1). Interestingly, a distinct PFKFB activity was 
detected in the testes [5] and a human testes-specific 
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PFKFB4 gene then was cloned in 1999 [6] suggesting 
that the unique metabolic requirements of sperm may 
necessitate a divergent PFKFB family member. Although 
several reports indicated that the testes PFKFB4 from 
various species display approximately 3-5 fold higher 
kinase than phosphatase activity [5, 7, 8], suggesting that 
its function was predominantly to increase glycolytic flux 
into the 3-carbon portion of the pathway, one study of 
purified protein reported a near 1:1 ratio similar to that of 
the liver PFKFB1 family member [9]. 
In the early 2000s, Minchenko et al. demonstrated 
that the testes PFKFB4 was induced by hypoxia in 
multiple cancer cell lines and over-expressed in matched 
human lung, breast and colon tumor tissues relative 
to normal tissues from the same patients [10-13]. The 
functional requirement of PFKFB4 for tumor growth then 
was published in 2010 when researchers demonstrated that 
selective inhibition of PFKFB4 with siRNA suppressed 
the growth of human lung adenocarcinoma xenografts in 
athymic mice (U.S. Patent #8,283,332; PFKFB4 Inhibitors 
and Methods of Using the Same). The importance of 
PFKFB4 as a potential target for the development of 
cancer therapeutics was then significantly expanded in 
2012 by two independent groups that conducted unbiased 
screens for genes essential for cancer survival and found 
that PFKFB4 is required for both glioma stem-like 
cell [14] and prostate cancer cell survival [15] but not 
for normal cell survival. Taken together, these studies 
indicated that PFKFB4 may be a useful molecular target 
for the development of anti-neoplastic agents. 
An essential first step in developing anti-cancer 
agents that inhibit PFKFB4 is to determine whether the 
kinase or phosphatase domain of this bifunctional enzyme 
are active in neoplastic cells. Whereas the kinase activity 
will produce F2,6BP and increase flux down the glycolytic 
pathway producing ATP, the phosphatase activity will 
decrease F2,6BP, reduce PFK-1 activity and increase 
the oxidative pentose shunt activity and NADPH via the 
availability of glucose 6-phosphate which is in equilibrium 
with fructose 6-phosphate (F6P) through glucose 
6-phosphate isomerase. Given that the intracellular 
concentration of the substrate of the kinase domain (F6P) 
is >10,000 fold the substrate of the phosphatase domain 
(F2,6BP) in transformed cells (e.g. MCF-7 cells: F6P, 
50±24 nmol/mg protein [16]; F2,6BP, 2.97±.21 pmol/
mg protein [17]), we predicted that the kinase activity of 
PFKFB4 would be the dominant function of this enzyme 
in transformed cells. 
In the present study, we find that PFKFB4 functions 
primarily to produce F2,6BP, thus stimulating glycolytic 
flux to lactate and the Kreb’s cycle in order to generate 
ATP and anabolic precursors. Accordingly, the synthesis of 
small molecule inhibitors of the PFKFB4 kinase domain is 
anticipated to enable the development of novel agents for 
the treatment of cancer.
RESULTS
High Expression of PFKFB4 in Several Normal 
Tissues and in Lung Adenocarcinomas
We first conducted a simultaneous analysis of 
PFKFB1-4 mRNA expression in normal human tissues 
using real-time RT-PCR for each family member. We 
observed high expression of: PFKFB1 in liver and skeletal 
muscle; PFKFB2 in heart, lung, skeletal muscle, kidney, 
pancreas and testes; and PFKFB4 in placenta, lung, 
skeletal muscle, pancreas, spleen, prostate, testes, ovary, 
colon and leukocytes (Fig. 1A). PFKFB3, which has been 
characterized as being inducible [18] and ubiquitous [19], 
was expressed at very low levels in all tissues with the 
exception of leukocytes (Fig 1A). We then used multiplex 
RT-PCR and real-time RT-PCR to assess PFKFB1-4 
mRNA expression in normal lung tissues and adjacent 
lung adenocarcinomas from five patients. Only PFKFB4 
mRNA was over-expressed in each of these patients’ 
tumors (Fig. 1B, C). Further examination of a larger cohort 
of lung adenocarcinomas and adjacent normal tissues from 
18 patients by immunohistochemical analyses revealed 
high PFKFB4 protein expression relative to normal lung 
alveoli (Fig. 1D, E). 
The Kinase:Phosphatase Ratio of PFKFB4 is 4.3:1 
and Selective Inhibition of PFKFB4 Expression 
Reduces F2,6BP in Multiple Cancer Cell Lines
We expressed and purified recombinant human 
PFKFB4 and compared the kinase and phosphatase 
activities to those of the inducible PFKFB3 recombinant 
protein. Given the recent reports that PFKFB4 functions 
as a dominant bisphosphatase in cancer cells [15], we 
were surprised to find that recombinant human PFKFB4 
had significant kinase activity that was ~15% that of 
the PFKFB3 family member whose kinase domain 
has previously been established to set the intracellular 
concentration of F2,6BP in multiple cell lines (PFKFB4 
kinase Vmax = 5.06±0.2 mU/mg, PFKFB3 kinase Vmax= 
38.4 ±2.3 mU/mg) (Fig. 2A) [18, 20, 21]. In contrast, 
both PFKFB4 and PFKFB3 were found to have relatively 
low phosphatase activities (PFKFB4 bisphosphatase 
Vmax = 1.17±0.02 mU/mg; PFKFB3 bisphosphatase Vmax 
= 0.47±0.035 mU/mg) and the kinase:bisphosphatase 
ratios for PFKFB4 and PFKFB3 were calculated to 
be 4.3:1 and 81.7:1, respectively (Fig. 2A). Since the 
concentration of the kinase substrate, F6P, is so much 
higher than that of the bisphosphatase substrate, F2,6BP 
(e.g. H460 cell [F6P] = 12518±1104 pmol/mg protein; 
[F2,6BP] = 4.47±.21 pmol/mg protein) and because the 
kinase:phosphatase is 4.3:1, we predicted that selective 
inhibition of PFKFB4 would preferentially inhibit the 
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kinase function of this bifunctional enzyme and thus 
result in a reduction in F2,6BP. We found that this did 
indeed occur in six out of seven transformed cancer cell 
lines derived from lung, colon, prostate and breast that 
were each transfected with two separate PFKFB4-specific 
siRNAs (Fig. 2B). Importantly, genomic deletion of Pfkfb4 
in LT-immortalized fibroblasts also caused a marked 
reduction in F2,6BP (Fig. 2C). Since PFKFB3, unlike 
PFKFB4, has been established to function as a kinase in 
transformed cells, we next examined the effect of PFKFB3 
siRNA transfection on three transformed cell lines and 
similarly observed a marked reduction in the steady-state 
concentration of F2,6BP (Fig. 2D). 
Selective Inhibition of PFKFB4 Expression 
Reduces Glycolysis and ATP in Multiple Cancer 
Cell Lines
We examined the effect of the two PFKFB4 siRNA 
molecules and genomic deletion of Pfkfb4 on glycolysis 
(measured by the production of 3H2O from [5-
3H]glucose), 
ATP and NADPH. We predicted that if the kinase function 
of PFKFB4 is dominant, then PFKFB4 inhibition would 
suppress (rather than increase) glycolysis and decrease 
the concentration of ATP which is produced downstream 
of PFK-1. We found that both glycolysis and ATP were 
reduced in all five cell lines examined although the ATP 
Figure 1: PFKFB4 Is Expressed in Multiple Normal Tissues and Over-Expressed in Human Lung Adenocarcinomas. 
PFKFB1-4 mRNA expression in multiple normal tissues was assessed by real-time RT-PCR and expressed by copy number (A). Matched 
normal (N) and lung adenocarcinoma (T) tissue were analyzed by multiplex RT-PCR (B) and by real-time RT-PCR expressed as fold 
change relative to adjacent normal tissues (C). Immunohistochemical staining of lung adenocarcinomas and normal lung was conducted on 
patients’ biopsies, three representative sections are shown (D) and positive pixels were quantitated (E). Data are expressed as the mean ± 
SD of three experiments. *p value < 0.001 compared to normal tissue controls.
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Figure 2: Recombinant PFKFB3 and PFKFB4 Kinase and Phosphatase Activities and Effects of PFKFB3 and 
PFKFB4 Inhibition on Intracellular F2,6BP in Cancer Cells. Human PFKFB3 and PFKFB4 were expressed and relative kinase 
and phosphatase specific activities (S.A.) were determined (A). The indicated cancer cell lines were transfected with control siRNA (Ctrl) 
or two PFKFB4 siRNAs (FB41 and FB42) and, after 48 hours, protein expression examined by Western blot and quantitated by densitometry 
and intracellular F2,6BP was measured (B). Large T antigen-immortalized, tamoxifen (4OHT)-inducible Pfkfb4-/- lung fibroblasts were 
exposed to 1 nM and 10 µM 4OHT (ethanol used as vehicle control) and analyzed for protein expression and F2,6BP after 48 hours (C). The 
indicated cancer cell lines were transfected with an established PFKFB3 siRNA and analyzed for protein expression and F2,6BP 48 hours 
later (D). Data are expressed as the mean ± SD of three experiments. * p value <0.001 compared to vehicle or control siRNA.
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depletion in MCF-7 cells was not statistically significant 
(Fig. 3A). Although we observed variable effects on 
NADPH, we did find that PFKFB4 inhibition increased 
NADPH in H460, A549, LNCaP and MCF-7 cells, 
presumably as a result of increased availability of F6P 
for the activity of glucose 6-phosphate isomerase and the 
oxidative pentose shunt (Fig. 3A). Importantly, we found 
that Pfkfb4 genomic deletion reduced glycolysis and ATP 
and increased NADPH, all findings consistent with a 
requirement of PFKFB4 for the activation of PFK-1 (Fig. 
3B).
Over-Expression of PFKFB4 Increases F2,6BP, 
Glycolysis and ATP and reduces NADPH
Given that the kinase activity of PFKFB4 is 4.3-
fold the phosphatase activity and that PFKFB4 siRNA 
transfection and genomic deletion both reduced F2,6BP, 
we predicted that over-expression would have the 
opposite effect on F2,6BP and subsequent metabolic 
events. We found that PFKFB4 over-expression increased 
F2,6BP, glycolysis and ATP, and decreased NADPH in 
each of the examined transformed cell lines (Fig. 4). We 
also examined the effect of addition of 5 mM pyruvate 
on the depletion of ATP caused by PFKFB4 siRNA in 
H460 cells and found that pyruvate partially reversed the 
ATP depletion, further supporting a role for PFKFB4 in 
increasing the glycolytic production of ATP (ATP, pmoles/
µg protein: Ctrl siRNA, 39.9±0.2; PFKFB4 siRNA 
9.94±0.5; Ctrl siRNA + Pyruvate, 40.4±0.13; PFKFB4 
siRNA + pyruvate, 33.1± 1.1; p value < 0.01).
Figure 3: Effects of PFKFB4 Inhibition on Cancer Cell Glycolysis, ATP and NADPH. The indicated cell lines were transfected 
with control siRNA (Ctrl) or two PFKFB4 siRNAs (FB41 and FB42) and glycolysis (3H2O production from [5-
3H]glucose), intracellular 
ATP and NADPH were measured (A). Large T antigen-immortalized, tamoxifen (4OHT)-inducible Pfkfb4-/- lung fibroblasts were exposed 
to 1 nM and 10 µM 4OHT and analyzed for glycolysis, ATP and NADPH 48 hours later (B). Data are expressed as the mean ± SD of three 
experiments. * p value <0.01 compared to vehicle or control siRNA.
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Inhibition of PFKFB4 Suppresses H460 Lung 
Adenocarcinoma F2,6BP, Glucose Uptake and 
Growth In Vivo
In order to determine if PFKFB4 functions to 
synthesize F2,6BP in vivo, we stably transfected H460 
cells with PFKFB4 shRNA and confirmed reduced 
PFKFB4 protein expression in vitro (Fig 5A). We found 
that stable PFKFB4 inhibition reduced anchorage-
independent growth as soft agar colonies and as tumors 
(Fig. 5A, B). We then examined resected tumors after 
two weeks of growth and observed a marked reduction 
in tumor F2,6BP and ATP and an increase in apoptotic 
cells in the tumors by immunohistochemistry for cleaved 
caspase 3 (Fig 5C, D, F) We also found a small increase 
in NADPH in the PFKFB4 shRNA tumors in comparison 
with control tumors which was not statistically significant 
(Fig 5E). In addition, we examined uptake of [18F]-FDG 
in PFKFB4 shRNA and control tumors by PET scan and 
observed reduced tumor [18F]-FDG uptake in the PFKFB4 
shRNA tumors (Fig. 5G) as has also been described as a 
result of PFKFB3 inhibition. Taken together, these in vivo 
studies provide strong evidence that PFKFB4 supports 
tumor growth by functioning as a kinase to synthesize 
F2,6BP.
Figure 4: Over-Expression of PFKFB4 in Cancer Cells Increases F2,6BP, Glycolysis and ATP but Decreases NADPH. 
The indicated cancer cell lines were transfected with either empty pCMV-XL4 (Vec) or pCMV-XL4 containing full-length PFKFB4 (+FB4) 
and analyzed 48 hours later by Western blot and densitometry, and for F2,6BP, glycolysis, ATP and NADPH. Data are expressed as the 
mean ± SD of three experiments. * p value < 0.01 compared to empty pCMV-XL4 vector.
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PFKFB4 mRNA and Protein Expression Are 
Increased by Hypoxia and Required for Hypoxia-
Induced F2,6BP, Glucose Uptake and Glycolysis
Both PFKFB3 and PFKFB4 mRNA previously have 
been found to be induced by hypoxia [10, 12, 13, 22-24] 
and we confirmed these past observations in H460 cells 
(Fig. 6A). In order to compare the functional relevance 
of PFKFB3 and PFKFB4 under hypoxic conditions, we 
transfected H460 cells with PFKFB4 or PFKFB3 siRNA 
under 21% and 1% oxygen. We observed a reduction in 
the hypoxic induction of both enzyme mRNAs as a result 
of the siRNA molecules (Fig. 6A). Hypoxia strongly 
induced PFKFB4 protein expression, as has been observed 
in other cell lines (Fig. 6A-C). Interestingly, we found a far 
lower induction of PFKFB3 protein which may already be 
maximally expressed as a result of the multitude of genetic 
alterations that increase PFKFB3 protein expression such 
as PTEN loss and Ras activation (e.g. H460 cells express 
KRASQ61H) [20, 25, 26]. Importantly, transfection with 
either PFKFB4 or PFKFB3 siRNA caused an attenuation 
Figure 5: Stable shRNA Knock-Down of PFKFB4 Reduces Tumor Growth, Glucose Uptake and F2,6BP, and Increases 
Apoptosis. H460 cells were stably transduced with PFKFB4 (shFB4) or control (Control, Ctrl) shRNA and assessed for PFKFB4 and 
PFKFB3 protein expression by Western blot analysis (A), soft agar colony formation (A), tumor growth in athymic mice (B). F2,6BP 
concentration (C), ATP (D), and NADPH (E) were measured in tumors following resection. Data are expressed as the mean ± SD of three 
experiments. Tumor sections were examined for apoptosis by cleaved caspase 3 (CC3) immunohistochemistry, with representative images 
on the left and positive pixels quantified on the right (F). The data is depicted as % positive pixels/total pixels ± SD. Tumors in mice 
were examined for 18F-FDG uptake in vivo by micro-PET imaging. Regions of interest in the tumors and cerebellum were quantified in 
quadruplicate (right) and representative transverse cuts are shown on the left (G). *p value < 0.001 compared to control shRNA.
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of F2,6BP, glucose uptake and glycolysis stimulated by 
hypoxia (Fig. 6D-F). The concentrations of both ATP and 
NADPH were decreased under hypoxia and PFKFB4 
siRNA exacerbated the ATP decrease, indicating that 
PFKFB4 may be essential for the glycolytic response to 
hypoxia in these cells (Fig. 6G, H).
PFKFB3 or PFKFB4 Inhibition in H460 Cells 
Reduces Glycolytic Flux to Lactate and Glutamate
Given that both PFKFB3 and PFKFB4 siRNA 
suppressed hypoxia-induced F2,6BP, we suspected 
that inhibition of PFKFB3 or PFKFB4 would result in 
Figure 6: Role of PFKFB3 and PFKFB4 in Hypoxia-Induced F2,6BP production, Glucose Uptake, Glycolysis, ATP 
and NADPH. H460 cells were transfected with control siRNA (siCtrl), PFKFB3 siRNA (siFB3) or PFKFB4 siRNA (siFB4), cultured in 
21% oxygen or 1% oxygen and examined for PFKFB3 and PFKFB4 mRNA expression (A) and protein expression by Western blot analysis 
and densitometry (B and C), F2,6BP (D), 14C-2-DG uptake (E), glycolysis (3H2O production from [5-
3H]glucose) (F), intracellular ATP (G) 
and NADPH (H). Data are expressed as the mean ± SD of three experiments. * p value < 0.01 compared to control siRNA.
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reduced glycolytic flux to lactate and into the TCA cycle 
product, glutamate, under hypoxic conditions. Whereas 
we found that both PFKFB3 and PFKFB4 siRNAs caused 
a reduction in the conversion of 13C-glucose to lactate 
and glutamate as assessed by NMR, the PFKFB4 siRNA 
caused a far greater reduction in the conversion to both 
products under both normoxic and hypoxic conditions 
(Fig. 7A, B). 
PFKFB3 or PFKFB4 Inhibition in H460 Cells 
Increases Apoptosis Under Normoxic and Hypoxic 
Conditions
Maintenance of intracellular ATP is required 
to prevent apoptosis and we postulated that PFKFB3 
or PFKFB4 inhibition would increase apoptosis. We 
observed a marked increase in apoptotic PI+/Annexin V+ 
Figure 7: Role of PFKFB3 and PFKFB4 in the Conversion of 13C-Glucose into 13C-Lactate and 13C-4-Glutamate. H460 
cells were transfected with control siRNA (siCtrl), PFKFB3 siRNA (siFB3) or PFKFB4 siRNA (siFB4), cultured in 21% oxygen or 1% 
oxygen, pulsed with uniformly-labeled 13C-glucose for hours and extracted for NMR analyses of 13C-lactate and 13C-4-glutamate. (A) 
1D NMR spectra of media extracts showing the region corresponding to the methyl groups of lactate and essential amino acids. Satellite 
peaks were integrated and normalized to internal DSS concentration to give the concentrations noted. Under these conditions, nearly all 
of the lactate derives from glucose. (B) 1D 1H{13C} HSQC spectra of cellular extracts showing selective enrichment at the C4 atom of 
glutamate (Glu) under normoxia, (21 % O2, left) and under hypoxia (1% O2, right). The C4 position of Glu becomes enriched by addition 
of glucose-derived acetate to oxaloacetate. The resulting 13C2 citrate is converted by the TCA cycle to 2-oxoglutarate and transaminated 
to Glu, showing that the TCA cycle remains active in these cells, but is greatly reduced under 1% oxygen and by PFKFB3 and PFKFB4 
knockdown. Values on the right denote ratios of peak areas normalized to uridine ribose (Urib) H1’, which correspond to relative amounts 
of glucose-derived 13C. Numbers expressed are the mean ± SD of three experiments.
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cells and cleaved PARP with inhibition of either family 
member under both normoxia and hypoxia but observed 
the greatest number of apoptotic cells as a result of the 
combination of hypoxia and PFKFB4 inhibition (Fig. 8A-
C).
PFKFB4 Expression Correlates With Hypoxia in 
Human Lung Adenocarcinoma Xenografts
We examined serial sections of human H460 lung 
adenocarcinoma xenograft tumors resected from athymic 
mice for expression of PFKFB4 and PFKFB3 and 
correlated the expression levels of these proteins using 
carbonic anhydrase IX, a potent transcriptional target of 
HIF-1α, as a hypoxia marker. We observed a statistically 
significant correlation between PFKFB4 and carbonic 
anhydrase IX expression but observed no correlation 
between PFKFB3 and carbonic anhydrase IX (Figure 9A-
D).
DISCUSSION
The main objective of this study was to determine 
which of the two enzymatic domains of PFKFB4 is 
Figure 8: Effect of PFKFB3 or PFKFB4 siRNA Transfection on Apoptosis. H460 cells were transfected with control siRNA 
(siCtrl), PFKFB3 siRNA (siFB3) or PFKFB4 siRNA (siFB4), cultured in 21% oxygen or 1% oxygen for 48 hours, and analysed for 
apoptosis by flow cytometry of propidium iodide and annexin V positive cells (A and B, PI+ + PI/Ann V+ cells shown as % apoptotic cells) 
and by cleaved PARP by Western blot analysis and densitometry (C). Data are expressed as the mean ± SD of three experiments. * p value 
< 0.005 compared to control siRNA.
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active in transformed cells. Using multiple cell types 
and approaches, we found that: (i) recombinant human 
PFKFB4 has far more kinase activity than phosphatase 
activity (kinase:phosphatase ratio = 4.3:1); (ii) selective 
inhibition of PFKFB4 using two unique siRNA molecules 
reduces the intracellular F2,6BP in six of seven cancer 
cell lines indicating that endogenous PFKFB4 synthesizes 
F2,6BP in these cancer cells; (iii) over-expression of 
PFKFB4 increases the F2,6BP in all examined cancer 
cell lines; and (iv) genomic deletion of the Pfkfb4 gene 
reduces F2,6BP in LT-immortalized fibroblasts. Taken 
together, these in vitro data provide overwhelming 
evidence that the main biochemical function of PFKFB4 is 
to synthesize F2,6BP. We also found that PFKFB4 siRNA 
reduces glycolysis and ATP and increases the steady-state 
concentration of NADPH in vitro, all expected metabolic 
effects of reduced F2,6BP. Additionally, we observed that 
PFKFB4 shRNA suppressed the glucose uptake, F2,6BP, 
ATP and growth of H460 xenograft tumors in mice, 
thus providing further evidence that the main function 
of PFKFB4 in vivo is to synthesize F2,6BP and thus 
activate PFK-1 and glycolysis. The rescue of transformed 
cells from PFKFB4 inhibition with the addition of 
pyruvate, which provides substrate for mitochondrial 
ATP production, provides further support that PFKFB4 is 
predominantly functioning to stimulate ATP production. 
To summarize, these data indicate that the kinase activity 
and, thus, the capacity to produce F2,6BP, serves as the 
dominant function of PFKFB4 in cancer cells. 
Since the majority of human cancers display 
elevated glucose uptake and several targeted agents 
such as the BRAF inhibitor, vemurafenib, and the 
estrogen antagonist, fulvestrant, acutely suppress glucose 
metabolism in order to inhibit tumor growth [17, 27], we 
believe that PFKFB3 and PFKFB4 kinase inhibitors may 
prove effective for the treatment of cancer. Importantly, 
Figure 9: PFKFB4 Expression Correlates with Hypoxia In Human Lung Adenocarcinoma Xenografts. Ten human 
H460 lung adenocarcinoma xenografts were analyzed by immunohistochemistry for carbonic anhydrase (CA) IX, PFKFB3 and PFKFB4. 
Representative adjacent sections from two tumors are provided (A,B). 20X magnification of portion of tumor in (B) shown (C). Positive 
pixels were enumerated in a minimum of 5 fields per tumor section followed by linear regression analysis (D). r2 and p values are provided.
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a novel family of related small molecule antagonists of 
the kinase domain of PFKFB3 (i.e. 3PO, PFK15 and 
PFK158) have been found to reduce glycolytic flux, ATP 
and cancer cell viability [17, 21, 28]. PFK158 is now 
being tested in a phase I clinical trial of advanced cancer 
patients (clinicaltrials.gov #NCT02044861) and recently 
has been found to synergistically interact with targeted 
cancer agents [17]. Given that PFKFB3 and PFKFB4 
are co-expressed in several cancer cell lines and have the 
redundant function of synthesizing F2,6BP, we postulate 
that selective inhibition of a single family member may 
result in compensation by a co-expressed PFKFB family 
member, and that combinations of PFKFB3 and PFKFB4 
inhibitors may be necessary in order to fully suppress 
tumor glucose metabolism and growth. Future studies will 
be directed at creating double Pfkfb3 and Pfkfb4 knockout 
mice in order to conduct in vivo studies of the roles of 
these two seemingly redundant enzymes in regulating the 
glucose metabolism and growth of tumors. 
Although this is the first comprehensive analysis of 
the relative importance of the kinase activity of PFKFB4 
in transformed cells to include a measurement of human 
recombinant protein activity and a combination of siRNA 
knock-down, plasmid-based over-expression and genomic 
deletion experiments in multiple cancer cell types, two 
prior studies previously have supported the conclusion 
that the kinase domain of PFKFB4 was essential for 
cancer cell proliferation. A PFKFB4 siRNA was found 
to reduce F2,6BP and glycolytic flux to lactate in A549 
lung adenocarcinoma cells (U.S. Patent #8,283,332) and 
two other PFKFB4 siRNAs were independently observed 
to reduce lactate secretion and the intracellular ATP in 
malignant glioma cells [14]. However, a third study found 
that PFKFB4 siRNA increased the F2,6BP concentration 
of three prostate cancer cell lines [15] including the 
LNCaP and PC3 cell lines (using one of the two siRNAs 
examined in the current study). Although it is difficult to 
reconcile the findings from this single discordant report 
with those of the other two studies as well as the present 
study, we believe that the combined use of recombinant 
protein analyses, cell lines derived from several types 
of cancer, two methods to inhibit PFKFB4 (siRNA 
and genomic deletion) and PFKFB4 over-expression 
experiments provide comprehensive and compelling data 
demonstrating that the kinase activity of PFKFB4 dictates 
the F2,6BP concentration in transformed cells. Whereas 
we look forward to continued independent examinations 
of the biochemical functions of PFKFB4 in transformed 
cells, our current data support an essential role of the 
PFKFB4 kinase activity for cancer cell survival as well as 
the development of small molecule antagonists that target 
the kinase domain of PFKFB4. 
Although the differences in metabolic functions of 
PFKFB3 and PFKFB4 are poorly understood, we observed 
a more robust induction of PFKFB4 protein relative upon 
exposure of H460 cells to 1% oxygen and significant 
correlation between hypoxia and PFKFB4 expression in 
lung adenocarcinoma tissues. Additionally, we detected 
a greater reduction in glycolytic flux to glutamate and 
lactate caused by PFKFB4 siRNA relative to PFKFB3 
siRNA transfection. Given these results, we suspect that 
PFKFB4 may serve as a unique regulator of the glycolytic 
response to hypoxia. This hypothesis is supported by 
the observation that the H460 cells underwent increased 
hypoxia-associated apoptosis when subjected to PFKFB4 
siRNA transfection but not when subjected to PFKFB3 
siRNA transfection. These data suggest that tumors that 
are especially affected by poor vasculature and hypoxia 
may be most responsive to PFKFB4 inhibition. 
CONCLUSIONS
In conclusion, our data indicate that the PFKFB4 
family member functions predominantly to synthesize 
F2,6BP which, in turn, is required for glycolytic flux 
through PFK-1 and subsequent ATP production. This 
conclusion is consistent with the finding that H460 cells 
are exquisitely sensitive to PFKFB4 inhibition under 
hypoxic conditions when the efficiency of ATP production 
by the mitochondria is compromised and the reliance 
on glycolysis to produce ATP is greatest. With the key 
intramolecular target of PFKFB4 now established, we 
believe that PFKFB4 inhibitors can be rationally designed 
and that these agents may prove most useful when 
combined with PFKFB3 inhibitors in order to circumvent 
potential compensation between these two PFKFB family 
members.
METHODS
Cell lines and cell culture
A549 and H460 NSCLC, MCF7 breast 
adenocarcinoma, LNCaP, PC3 and DU145 prostatic 
adenocarcinoma and HCT116 colon adenocarcinoma 
cell lines were obtained from ATCC (Manassas, VA). 
PFKFB4-/- ear pinna fibroblasts were isolated from 
TamCre/loxP/PFKFB4-/- mice and immortalized by 
transduction with REBNA/IRES retrovirus expressing 
SV40 large T antigen as described previously [20]. 
Cell lines were grown in DMEM (A549, LNCaP, PC3, 
DU145 and PFKFB4-/-), RPMI 1640 (H460), McCoy’s 5A 
media (HCT116) or improved MEM (MCF7) (all from 
Invitrogen, Grand Island, NY) containing 10% fetal calf 
serum (FCS, Hyclone, Logan, UT) at 37ºC in 5% CO2. 
In some experiments, 4-hydroxytamoxifen (4OHT, 4HT, 
Sigma -Aldrich, St. Louis, MO) was added to PFKFB4 
-/- fibroblasts at indicated concentrations.
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Transfections
For siRNA experiments, cells growing in 6-well 
plates were transfected with control siRNA (Stealth 
Negative Control Medium GC Duplex, Invitrogen), 
PFKFB3 siRNA (FB3; HSS107860, Invitrogen) or 
PFKFB4 siRNA (FB41, FB4; HSS107863, Invitrogen and 
FB42; siGENOME human PFKFB4 5210 #2, Dharmacon) 
using Lipofectamine RNAiMax (Invitrogen, Carlsbad, 
CA), and harvested 48 hours after transfection. For 
hypoxia experiments, cells were transfected with siRNA 
and, after 24 hours, were placed in a hypoxia chamber 
(Billups-Rothenburg, Del Mar, CA) purged with 1% 
oxygen for 24 hours. For short hairpin RNA (shRNA) 
experiments, sense and antisense DNA oligonucleotides 
for PFKFB4 were designed with a hairpin against 
the target sequences 5’-cacttgtatggtcctgt-3’ and 
5’-ggagagcgaccatcttt-3’ were produced by IDT (Coralville, 
IA). The oligonucleotides were annealed and ligated into 
pSUPER.neo vector (OligoEngine, Seattle, WA) following 
manufacturer’s instructions. H460 cells were transfected 
with an shRNA-expressing plasmid targeted against 
PFKFB4 (shFB4) or a scrambled shRNA expressing 
plasmid (Control) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) and clones selected with G418 (500 µg/ml). 
For overexpression experiments, cells were transfected 
with pCMV-XL4 (vector) or pCMV-XL4 containing 
full-length PFKFB4 (Origene, Rockville, MD) using 
Lipofectamine 2000 and harvested after 48 hours. 
PCR analyses
Multiplex mRNA primers were custom synthesized 
(IDT) against human PFKFB1-4 as described previously 
[20]. cDNA from normal human tissues and matched 
tumor and adjacent normal tissues (Clontech, Mountain 
View, CA) were analyzed using these primers and standard 
PCR conditions. PFKFB1-4 mRNA expression was 
determined using real-time RT-PCR with TaqMan probes 
for human PFKFB1-4 and β-actin (Applied Biosystems, 
Foster City, CA) in triplicate in 96-well optical plates 
(MicroAMP®, Applied Biosystems). Analysis of 
results and fold differences between samples were 
determined using StepOne software (version2.1) (Applied 
Biosystems) and calculated from the ΔΔCT values with 
the formula (2-ΔΔCT). The data are represented as the mean 
± SD from triplicate measurements from three independent 
experiments. For calculation of copy number, the 
molecular weight was determined for the double stranded 
DNA sequences of the 4 PFKFB isoforms. The OD of the 
DNA (in gm/μL) was divided by the molecular weight of 
the product (result in moles/μL) and then this number was 
multiplied by Avogadro’s number (6.022 × 1023 molecules/
mole). The resulting number of DNA molecules per μL 
was used to generate a standard curve from which copy 
numbers were calculated. Statistical significance was 
assessed by the two-sample t test (independent variable).
Protein extraction and Western blotting
Cells were harvested, washed X1 in PBS and lysed 
in 1X lysis buffer (Pierce Biotechnology, Rockford, IL) 
containing protease inhibitors. Protein samples were 
resolved on 4-20% SDS-PAGE gels (BioRad, Hercules, 
CA) and transferred to PVDF membranes (BioRad). After 
blocking in TBS containing 0.1% Tween 20 (TBS-T) and 
5% milk, membranes were probed with antibodies to 
PFKFB3 (Proteintech, Chicago, IL), PFKFB4 (Abcam, 
Cambridge, MA) or β-actin (Sigma, St. Louis, MO). 
Secondary antibodies used were HRP-conjugated goat 
anti-rabbit or anti-mouse (1:5000, Pierce Biotechnology). 
Scanned images were quantified by densitometric analyses 
using Image J software (http://rsb.info.nih.gov/ij/). Values 
obtained were normalized to β-actin and expressed 
in densitometric units as a percentage of control. The 
data represented are the mean ± SD from triplicate 
measurements from three independent experiments. 
Statistical significance was assessed by the two-sample t 
test (independent variable).
Kinase and Bisphosphatase assays
Fructose-6-phosphate kinase and fructose-2,6-
bisphosphatase activities of human recombinant PFKFB3 
and PFKFB4 were assayed using previously described 
methods wherein one unit of activity was defined as the 
amount of enzyme that catalyzes the formation of 1 µmol 
of F2,6BP per min. [7, 8]. Aliquots of the reaction mixture 
were removed at intervals, added to 0.1N NaOH and then 
neutralized to a pH of 7.2 and assayed for F2,6BP as 
described below. 
F2,6BP measurements
Cells were harvested, washed twice with PBS, lysed 
in NaOH/Tris acetate by heating at 80°C for 5 min. Lysates 
were neutralized to pH 7.2 with ice-cold acetic acid and 
HEPES. F2,6BP content was measured using a coupled 
enzyme reaction following the method of Van Schaftingen 
et al [29]. The F2,6BP concentration was normalized to 
total cellular protein measured by the bicinchoninic acid 
assay (BCA, Thermo Scientific, Rockford, IL). All data 
are expressed as the mean ± SD of three experiments. 
Statistical significance was assessed by the two-sample t 
test (independent variable).
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Glycolysis assay
Cells growing in 6-well plates were incubated in 
500 μl of complete medium containing 1 μCi of 5-[3H]
glucose per well for 60 min in 5% CO2 at 37°C. The 
medium was then collected and centrifuged for 5 min at 
8000 rpm to pellet any suspended cells. To separate the 
3H2O formed via glycolysis from the 5-[
3H]glucose added 
to the medium, an evaporation technique in a sealed 
system was utilized. Briefly, 150 μl aliquots of medium 
were added to open tubes that were placed upright inside 
scintillation vials containing 1 ml of H2O. The scintillation 
vials were sealed, and the 3H2O produced by glycolysis 
through enolase and released to the medium was allowed 
to equilibrate with the H2O in the outer vial for 48 h at 
37°C. The amounts of 3H2O that had diffused into the 
surrounding H2O was measured on a Tri-Carb 2910 liquid 
scintillation analyzer (Perkin Elmer, Boston, MA) and 
compared with 3H2O and 5-[
3H]glucose standards. Protein 
concentration was determined using the BCA assay and 
counts were normalized to protein concentration. All data 
are expressed as the mean ± SD of three experiments. 
Statistical significance was assessed by the two-sample t 
test (independent variable).
2-[1-14C]-Deoxy-D-Glucose Uptake
Cells were placed in glucose-free media for 30 
minutes, 2-[1-14C]-deoxy-D-glucose (0.25 μCi/mL; 
Perkin Elmer) was added for an additional 60 min and 
the cells then were washed thrice with ice-cold glucose-
free media. Cell lysates were collected in 500 μL of 
0.1% SDS, and scintillation counts (counts/min) were 
measured on 400 μL of the lysate. Counts were normalized 
to protein concentration measured by the BCA assay 
and data are represented as mean ± SD from triplicate 
measurements from three independent experiments. 
Statistical significance was assessed by the two-sample t 
test (independent variable).
ATP Measurements
Cell pellets were lysed using Passive Lysis buffer 
(1X, Molecular Probes, Invitrogen). Lysates were flash 
frozen in liquid nitrogen and thawed (to 37ºC) once to 
accomplish complete lysis and then centrifuged at 4ºC 
for 30 seconds to clear the lysates. Intracellular ATP 
levels were determined using a bioluminescence assay 
(Molecular Probes, Eugene, OR) utilizing recombinant 
firefly luciferase and its substrate, d-luciferin and 
following manufacturer’s instructions. The luminescence 
was read in a TD-20/20 luminometer (Turner Designs, 
Sunnyvale, CA) at 560 nm. The ATP values were 
calculated using an ATP standard curve. The protein 
concentrations of the lysates were estimated using 
the BCA assay and ATP was expressed as pmol per µg 
protein. All data are expressed as the mean ± SD of three 
experiments. Statistical significance was assessed by the 
two-sample t test (independent variable).
NADPH Measurements
Cells were harvested, washed with ice cold 
PBS and homogenized in NADPH extraction buffer 
(EnzyFluo, Bioassay Systems, Hayward, CA). NADPH 
was then measured following manufacturer’s instructions 
(Bioassay Systems) by reduction of the provided probe 
into a fluorescent product measured at λex/em of 530/585 
nm. Values were compared with a standard curve. All data 
are expressed as the mean ± SD of three experiments. 
Statistical significance was assessed by the two-sample t 
test (independent variable).
Apoptosis Assay
Cells were stained with FITC-labeled annexin-V and 
propidium iodide following the manufacturer’s protocol 
(BD Biosciences, San Diego, CA). Briefly, cells were 
detached and 100,000 cells per sample were pelleted by 
centrifugation at 1500 rpm for 5 minutes and washed X1 
with PBS. The cells were then resuspended in 1X binding 
buffer, annexin-V/FITC and/or propidium iodide added 
and were incubated in the dark at room temperature for 
15 minutes. 1X binding buffer was added to increase 
volume and 10,000 events were counted for each sample 
using the appropriate filters for FITC and PI detection 
(BD FACSCalibur, San Jose, CA). Data was analyzed 
using FlowJo software (TREE STAR Inc, San Carlos, 
CA). Results were calculated as the average of triplicate 
samples ± SD.
NMR Experiments
Cells treated with siRNA were grown in media 
containing uniformly labeled 13C-glucose (2 gm/L, 
Cambridge Isotopes Laboratories, Andover, MA) for 24 
hours. Media samples were frozen in liquid nitrogen. 
Cells were counted and equal numbers of cells were 
pelleted, washed twice with cold PBS to remove adhering 
medium, and flash frozen in liquid nitrogen. The cell 
pellets and media samples were extracted with 10% ice-
cold trichloracetic acid (TCA) followed by lyophilization. 
The extracts were redissolved in D2O containing 85 
µM (media) or 95 µM (cells) DSS (2, 2-dimethyl-2-
silapentane-5-sulfonate sodium salt) as both a chemical 
shift reference and as a concentration standard and loaded 
into 5 mm Shigemi tubes (Shigemi, Tokyo, Japan). 
Nuclear magnetic resonance (NMR) spectra were recorded 
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at 14.1 T on a Varian Inova spectrometer at 20°C using 
a 90° excitation pulse as described previously [30]. 1D 
proton NMR spectra of extracts were recorded with a 2 
sec acquisition time and a total recycle time of 5 sec, with 
presaturation of the residual HOD resonance for 3 seconds. 
For analyzing the cellular extracts and determining the 
positional enrichment with 13C we used 2D experiments 
(TOCSY and 1H{13C}-HSQC), and quantified the 13C 
satellite and 12C peaks by volume integration in the 
TOCSY using established assignment protocols [30, 31]. 
The NMR experiments were carried out in the Structural 
Biology Program’s NMR Core at the University of 
Louisville James Graham Brown Cancer Center.
Mouse Studies
H460 cells stably transfected with either PFKFB4 
or control shRNA were collected from exponential growth 
phase culture. Cells were washed twice, re-suspended in 
PBS (5 × 107 cells/ml) and groups of 10 BALB/c athymic 
female mice were injected s.c. with 100 µL (5 × 106 cells) 
of the cell suspension. The tumors were followed from 
the time of appearance until the end of the experiment. 
Tumor masses were determined in a blinded fashion 
with Vernier calipers according to the following formula: 
weight (mg) = (width, mm)2 × (length, mm)/2 [32]. All 
data are expressed as the mean ± SD of two experiments. 
Statistical significance was assessed by the two-sample t 
test (independent variable). At the end of the experiment, 
the animals were euthanized and tumors removed and 
fixed in 10% formaldehyde. Sections were stained with 
hematoxylin/eosin and for immunohistochemistry as 
described below. At the end of the experiment, subsets 
of xenograft-bearing mice (n=4) were injected i.p. with 
2-[18F]-fluoro-2-deoxyglucose (18F-FDG, 150µCi, 100 
µL in H2O) and, after 45 min, were anesthetized with 
2% isoflurane in oxygen and transferred to a R-4 Rodent 
Scanner (CTI Concorde Microsystems) micro-positron 
emission tomograph to capture images. Regions of 
interest in the tumors and cerebellum were quantified in 
quadruplicate and are expressed as the mean ± SD of the 
ratio of tumor:cerebellar FDG uptake. Animal experiments 
were carried out in accordance with established practices 
as described in the National Institutes of Health Guide for 
Care and Use of Laboratory Animals and were approved 
by the University of Louisville Institutional Animal Care 
and Use Committee.
Immunohistochemistry
Five μm mounted sections of formalin-fixed and 
paraffin-embedded tumor tissue were deparaffinized with 
xylene. Epitope retrieval was carried out using citrate 
buffer in a 2100 Retriever (PickCell Laboratories). The 
sections were blocked with 10% goat serum for 1 hour, 
then incubated with primary antibody against PFKFB3, 
PFKFB4, carbonic anhydrase IX (Proteintech) or cleaved 
caspase-3 (Cell Signaling, Danvers, MA) overnight, 
followed by an HRP-linked goat anti-rabbit secondary 
antibody (1:300, Pierce Biotechnology). The sections were 
developed with 3,3’-diaminobenzidine tetrahydrochloride 
(DAB, Vector Laboratories, Burlingame, CA) for 2 min, 
nuclei counterstained with Mayer’s hematoxylin (Sigma-
Aldrich) for 2 min and coverslips attached with Permount 
(Fisher Scientific, Fair Lawn, NJ). Slides were scanned 
using a ScanScope XT Digital Slide Scanner (Aperio), 
data analyzed with the positive pixel count algorithm 
(ImageScope, Aperio) and a minimum of 5 fields (20x 
magnification) were quantified for each tumor section. 
The data is depicted as % positive pixels/total pixels ± SD.
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